Seagate Technology Holdings PLC vs Viatris Inc — how do they compare? Seagate Technology Holdings PLC trades at $880.04 (market cap $205.65B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Seagate Technology Holdings PLC is far larger — about 10.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| STX | VTRS | |
|---|---|---|
Market Cap | $205.65B | $19.09B |
Sector | Technology | Health |
52-Week High | $1.09K | $17.86 |
52-Week Low | $193.04 | $9.49 |
Enterprise Value | $207.80B | $31.21B |
Dividend Yield | 0.33% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Seagate Technology (STX) trades at $904.38, up 6.49% today, with strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with support at $868 and resistance at $933. Recent earnings beats and robust 2026 revenue guidance of $12.2B highlight fundamental strength, though valuation ratios remain elevated with P/E at 65.06. Analyst consensus is bullish with a $1,130 price target, supported by institutional accumulation and positive media coverage of HAMR technology adoption.
Outlook: STX benefits from AI-driven storage demand and operational execution, but faces risks from high debt and competitive pressures. The stock's premium valuation requires sustained growth to justify upside. Near-term catalysts include Q3 earnings and product ramps, while macroeconomic volatility and execution missteps pose headwinds. Investor sentiment remains positive, but caution is warranted given rich multiples.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Trailing returns across standard periods
Latest headlines on both assets
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →